Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis

Clinical Biochemistry

Volumn 44, Issue 17-18, 2011, Pages 1405-1411

  Zheng, Yanan ^a   Chen, Lu ^a   Li, Jianfang ^a   Yu, Beiqin ^a   Su, Liping ^a   Chen, Xuehua ^a   Yu, Yingyan ^a   Yan, Min ^a   Liu, Bingya ^a   Zhu, Zhenggang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biomarkers; Diagnosis; Gastric cancer; Methylation

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450; CYTOCHROME P450 26B1; DNA; MESSENGER RNA; POTASSIUM CHANNEL KV1.4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PATIENT; COLON CANCER; CONTROLLED STUDY; DEMETHYLATION; DNA ISOLATION; DNA METHYLATION; DNA MICROARRAY; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DNA METHYLATION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; KV1.4 POTASSIUM CHANNEL; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 81555214109     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.09.006     Document Type: Article

References (62)

1. M. Sasako, M. Inoue, J.T. Lin, C. Khor, H.K. Yang, A. Ohtsu, Gastric Cancer Working Group report. Jpn J Clin Oncol 40 Suppl 1 i28-37.
2. R.M. Quiros, D.C. Desai, Multidisciplinary approach for the treatment of gastric cancer. Minerva Gastroenterol Dietol 57 53-68.
3. Tepes B. Can gastric cancer be prevented?. J Physiol Pharmacol 2009, 60(Suppl 7):71-77.
4. J. Wang, J.C. Yu, W.M. Kang, Z.Q. Ma, Treatment strategy for early gastric cancer. Surg Oncol.
5. Choi I.J. Gastric cancer screening and diagnosis. Korean J Gastroenterol 2009, 54:67-76.
6. Yeoh K.G. How do we improve outcomes for gastric cancer?. J Gastroenterol Hepatol 2007, 22:970-972.
7. T.L. Ang, C.J. Khor, T. Gotoda, Diagnosis and endoscopic resection of early gastric cancer. Singapore Med J 51 93-100.
8. A. Cappellani, A. Zanghi, M. Di Vita, E. Zanet, P. Veroux, B. Cacopardo, A. Cavallaro, G. Piccolo, E. Lo Menzo, P. Murabito, M. Berretta, Clinical and biological markers in gastric cancer: update and perspectives. Front Biosci (Schol Ed) 2 403-412.
9. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000, 16:168-174.
10. K. Yamashita, S. Sakuramoto, M. Watanabe, Genomic and epigenetic profiles of gastric cancer: Potential diagnostic and therapeutic applications. Surg Today 41 24-38.
11. Lee J.H., Park S.J., Abraham S.C., Seo J.S., Nam J.H., Choi C., Juhng S.W., Rashid A., Hamilton S.R., Wu T.T. Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 2004, 23:4646-4654.
12. Vincent A., Ducourouble M.P., Van Seuningen I. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. FASEB J 2008, 22:3035-3045.
13. Tamura G. Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol 2002, 17:323-329.
14. C.S. Rosenfeld, Animal models to study environmental epigenetics. Biol Reprod 82 473-488.
15. Delcuve G.P., Rastegar M., Davie J.R. Epigenetic control. J Cell Physiol 2009, 219:243-250.
16. Adcock I.M., Ford P., Ito K., Barnes P.J. Epigenetics and airways disease. Respir Res 2006, 7:21.
17. Y.J. Park, R. Claus, D. Weichenhan, C. Plass, Genome-wide epigenetic modifications in cancer. Prog Drug Res 67 25-49.
18. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6:107-116.
19. Gronbaek K., Hother C., Jones P.A. Epigenetic changes in cancer. APMIS 2007, 115:1039-1059.
20. Miranda E., Destro A., Malesci A., Balladore E., Bianchi P., Baryshnikova E., Franchi G., Morenghi E., Laghi L., Gennari L., Roncalli M. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 2006, 95:1101-1107.
21. Herman J.G. Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol 2005, 70:329-333.
22. R. Taby, J.P. Issa, Cancer epigenetics. CA Cancer J Clin 60 376-392.
23. Magic Z., Supic G., Brankovic-Magic M. Towards targeted epigenetic therapy of cancer. J BUON 2009, 14(Suppl 1):S79-S88.
24. K. Czarnecka, D. Pastuszak-Lewandoska, M. Migdalska-Sek, E. Nawrot, J. Brzezinski, M. Dedecjus, L. Pomorski, E. Brzezianska, Aberrant methylation as a main mechanism of TSGs silencing in PTC. Front Biosci (Elite Ed) 3 137-157.
25. R. Venkatachalam, M.J. Ligtenberg, N. Hoogerbrugge, D.R. de Bruijn, R.P. Kuiper, A. Geurts van Kessel, The epigenetics of (hereditary) colorectal cancer. Cancer Genet Cytogenet 203 1-6.
26. Cravo M., Pinto R., Fidalgo P., Chaves P., Gloria L., Nobre-Leitao C., Costa Mira F. Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. Gut 1996, 39:434-438.
27. Lofton-Day C., Model F., Devos T., Tetzner R., Distler J., Schuster M., Song X., Lesche R., Liebenberg V., Ebert M., Molnar B., Grutzmann R., Pilarsky C., Sledziewski A. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008, 54:414-423.
28. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003, 3:253-266.
29. Levenson V.V. DNA methylation biomarkers of cancer: moving toward clinical application. Pharmacogenomics 2004, 5:699-707.
30. Henrique R., Costa V.L., Jeronimo C. Methylation-based biomarkers for early detection of urological cancer. Crit Rev Oncog 2007, 13:265-282.
31. Brena R.M., Huang T.H., Plass C. Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med 2006, 84:365-377.
32. S.A. Qureshi, M.U. Bashir, A. Yaqinuddin, Utility of DNA methylation markers for diagnosing cancer. Int J Surg 8 194-198.
33. Y.A. Goo, D.R. Goodlett, Advances in proteomic prostate cancer biomarker discovery. J Proteomics 73 1839-1850.
34. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
35. D.R. Hodgson, R. Wellings, M.C. Orr, R. McCormack, M. Malone, R.E. Board, M.V. Cantarini, Circulating tumour-derived predictive biomarkers in oncology. Drug Discov Today 15 98-101.
36. V.V. Vlassov, P.P. Laktionov, E.Y. Rykova, Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 10 142-165.
37. Garcia-Olmo D.C., Ruiz-Piqueras R., Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 2004, 19:575-583.
38. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007, 635:105-117.
39. K. Washington, 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17 3077-3079.
40. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826.
41. Lee J.M., Garon E., Wong D.T. Salivary diagnostics. Orthod Craniofac Res 2009, 12:206-211.
42. Bassi P., De Marco V., De Lisa A., Mancini M., Pinto F., Bertoloni R., Longo F. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005, 75:193-200.
43. Kudlacek S. Tumor markers. Their current diagnostic status. Wien Med Wochenschr 1988, 138:228-242.
44. Angerer J., Ewers U., Wilhelm M. Human biomonitoring: state of the art. Int J Hyg Environ Health 2007, 210:201-228.
45. Ohtani M., Iwasaki A., Shiraiwa H. Urinary tumor marker for urothelial cancer. Gan To Kagaku Ryoho 2001, 28:1933-1937.
46. Tomonaga T., Nomura F. Novel tumor marker discovery of gastrointestinal cancers using various proteomic approaches. Rinsho Byori 2007, 55:63-68.
47. Goessl C., Muller M., Straub B., Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 2002, 41:668-676.
48. Cottrell S.E., Laird P.W. Sensitive detection of DNA methylation. Ann N Y Acad Sci 2003, 983:120-130.
49. Anker P., Mulcahy H., Chen X.Q., Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18:65-73.
50. Gao Y.J., Xin Y., Zhang J.J., Zhou J. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma. World J Gastroenterol 2008, 14:5000-5007.
51. Hosoya K., Yamashita S., Ando T., Nakajima T., Itoh F., Ushijima T. Adenomatous polyposis coli 1A is likely to be methylated as a passenger in human gastric carcinogenesis. Cancer Lett 2009, 285:182-189.
52. Ye M., Xia B., Guo Q., Zhou F., Zhang X. Association of diminished expression of RASSF1A with promoter methylation in primary gastric cancer from patients of central China. BMC Cancer 2007, 7:120.
53. Kang G.H., Lee S., Kim J.S., Jung H.Y. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003, 83:635-641.
54. de Maat M.F., van de Velde C.J., Umetani N., de Heer P., Putter H., van Hoesel A.Q., Meijer G.A., van Grieken N.C., Kuppen P.J., Bilchik A.J., Tollenaar R.A., Hoon D.S. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 2007, 25:4887-4894.
55. Maier S., Dahlstroem C., Haefliger C., Plum A., Piepenbrock C. Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics 2005, 5:223-232.
56. Graziano F., Humar B., Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003, 14:1705-1713.
57. Gu P., Xing X., Tanzer M., Rocken C., Weichert W., Ivanauskas A., Pross M., Peitz U., Malfertheiner P., Schmid R.M., Ebert M.P. Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia 2008, 10:563-572.
58. Chan A.W., Chan M.W., Lee T.L., Ng E.K., Leung W.K., Lau J.Y., Tong J.H., Chan F.K., To K.F. Promoter hypermethylation of death-associated protein-kinase gene associated with advance stage gastric cancer. Oncol Rep 2005, 13:937-941.
59. Dong W., Tu S., Xie J., Sun P., Wu Y., Wang L. Frequent promoter hypermethylation and transcriptional downregulation of BTG4 gene in gastric cancer. Biochem Biophys Res Commun 2009, 387:132-138.
60. Ushijima T., Sasako M. Focus on gastric cancer. Cancer Cell 2004, 5:121-125.
61. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
62. Diehl F., Li M., Dressman D., He Y., Shen D., Szabo S., Diaz L.A., Goodman S.N., David K.A., Juhl H., Kinzler K.W., Vogelstein B. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005, 102:16368-16373.